Drug Profile
Malaria vaccine live unattenuated plus chloroquine - Sanaria
Alternative Names: PfSPZ Challenge plus chloroquine; PfSPZ CVac; PfSPZ malaria vaccine live unattenuated plus chloroquine - Sanaria; Plasmodium falciparum sporozoite vaccine live unattenuated plus chloroquine - SanariaLatest Information Update: 09 Jul 2022
Price :
$50
*
At a glance
- Originator Sanaria
- Developer National Institute of Allergy and Infectious Diseases; Sanaria; University of Tubingen
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Falciparum malaria
Most Recent Events
- 01 Jul 2022 University Hospital Tuebingen in collaboration with Sanaria plans a phase I/II trial in Malaria (IV, Injection) in October 2022 (NCT05441410)
- 30 May 2022 Phase-II clinical trials in Falciparum malaria (In adults, Prevention) in Indonesia (IV) (NCT03503058)
- 27 Feb 2020 University of Oxford in collaboration with Sanaria plans a phase I/II trial for Malaria (In volunteers) in Kenya (NCT04280692)